Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Analyses of biomarkers of exposure to nephrotoxic mycotoxins in a cohort of patients with renal tumours

F. Malir, M. Louda, V. Ostry, J. Toman, N. Ali, Y. Grosse, E. Malirova, J. Pacovsky, D. Pickova, M. Brodak, A. Pfohl-Leszkowicz, GH. Degen,

. 2019 ; 35 (4) : 391-403. [pub] 20190629

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006201

Grantová podpora
2118/2015 University Hradec Kralove, Czech Republic
2113/2016 University Hradec Kralove, Czech Republic
2105/2017 University Hradec Kralove, Czech Republic
NIPH, IN 75010330 Ministry of Health, Czech Republic conceptual development of research organization

The Czech Republic occupies the first place in the world in the frequency of renal and other urinary tract tumours, but their aetiology is unknown. To explore whether carcinogenic and nephrotoxic mycotoxins may contribute to kidney diseases in the Czech population, biomarkers of ochratoxin A (OTA) and citrinin (CIT) exposure were determined in biological specimens from a cohort of 50 patients with malignant renal tumours. Biomarker analyses in blood and urine samples used validated targeted methods for measuring OTA and CIT plus dihydrocitrinone (DH-CIT) after enrichment of analytes by specific immunoaffinity clean-up. OTA and CIT plus its metabolite DH-CIT were frequently detected in patient urine samples (OTA 62%; CIT 91%; DH-CIT 100%). The concentration ranges in urine were 1-27.8 ng/L for OTA, 2-87 ng/L for CIT and 2-160 ng/L for DH-CIT. The analyses of blood samples revealed also a frequent co-occurrence of OTA and CIT, in the ranges of 40-870 ng/L serum for OTA and 21-182 ng/L plasma for CIT. This first analysis of biomarkers in blood and urine samples of Czech patients revealed no major differences in comparison with published data for the general healthy Czech and European populations. Nonetheless, a frequent co-occurrence of CIT and OTA biomarkers in patient samples may be of interest with regard to potential interactions with other risk factors for renal disease.

000      
00000naa a2200000 a 4500
001      
bmc20006201
003      
CZ-PrNML
005      
20200526143706.0
007      
ta
008      
200511s2019 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12550-019-00365-9 $2 doi
035    __
$a (PubMed)31254204
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Malir, Frantisek $u Department of Biology, Faculty of Science, University of Hradec Králové, Rokitanskeho 62,, 500 03, Hradec Kralove, Czech Republic. frantisek.malir@uhk.cz.
245    10
$a Analyses of biomarkers of exposure to nephrotoxic mycotoxins in a cohort of patients with renal tumours / $c F. Malir, M. Louda, V. Ostry, J. Toman, N. Ali, Y. Grosse, E. Malirova, J. Pacovsky, D. Pickova, M. Brodak, A. Pfohl-Leszkowicz, GH. Degen,
520    9_
$a The Czech Republic occupies the first place in the world in the frequency of renal and other urinary tract tumours, but their aetiology is unknown. To explore whether carcinogenic and nephrotoxic mycotoxins may contribute to kidney diseases in the Czech population, biomarkers of ochratoxin A (OTA) and citrinin (CIT) exposure were determined in biological specimens from a cohort of 50 patients with malignant renal tumours. Biomarker analyses in blood and urine samples used validated targeted methods for measuring OTA and CIT plus dihydrocitrinone (DH-CIT) after enrichment of analytes by specific immunoaffinity clean-up. OTA and CIT plus its metabolite DH-CIT were frequently detected in patient urine samples (OTA 62%; CIT 91%; DH-CIT 100%). The concentration ranges in urine were 1-27.8 ng/L for OTA, 2-87 ng/L for CIT and 2-160 ng/L for DH-CIT. The analyses of blood samples revealed also a frequent co-occurrence of OTA and CIT, in the ranges of 40-870 ng/L serum for OTA and 21-182 ng/L plasma for CIT. This first analysis of biomarkers in blood and urine samples of Czech patients revealed no major differences in comparison with published data for the general healthy Czech and European populations. Nonetheless, a frequent co-occurrence of CIT and OTA biomarkers in patient samples may be of interest with regard to potential interactions with other risk factors for renal disease.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a biologické markery $x krev $x moč $7 D015415
650    _2
$a chromatografie kapalinová $7 D002853
650    _2
$a citrinin $x krev $x moč $7 D002953
650    _2
$a kohortové studie $7 D015331
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a nádory ledvin $x chemie $x moč $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mykotoxiny $x krev $x moč $7 D009183
650    _2
$a ochratoxiny $x krev $x moč $7 D009793
650    _2
$a tandemová hmotnostní spektrometrie $7 D053719
651    _2
$a Československo $7 D003604
655    _2
$a časopisecké články $7 D016428
700    1_
$a Louda, Miroslav $u Medical School and Teaching Hospital, Department of Urology, Charles University, Sokolska 581,, 500 05, Hradec Kralove, Czech Republic.
700    1_
$a Ostry, Vladimir $u Department of Biology, Faculty of Science, University of Hradec Králové, Rokitanskeho 62,, 500 03, Hradec Kralove, Czech Republic. Center for Health, Nutrition and Food in Brno, National Institute of Public Health in Prague, Palackeho 3a, 612 42, Brno, Czech Republic.
700    1_
$a Toman, Jakub $u Department of Biology, Faculty of Science, University of Hradec Králové, Rokitanskeho 62,, 500 03, Hradec Kralove, Czech Republic.
700    1_
$a Ali, Nurshad $u Department of Biochemistry and Molecular Biology, Shahjalal University of Science and Technology, Sylhet, 3114, Bangladesh.
700    1_
$a Grosse, Yann $u International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372, Lyon Cedex 08, France.
700    1_
$a Malirova, Eva $u Department of Clinical Biochemistry, Charles University Medical School and Teaching Hospital, Sokolska 581, 50005, Hradec Kralove, Czech Republic.
700    1_
$a Pacovsky, Jaroslav $u Medical School and Teaching Hospital, Department of Urology, Charles University, Sokolska 581,, 500 05, Hradec Kralove, Czech Republic.
700    1_
$a Pickova, Darina $u Department of Biology, Faculty of Science, University of Hradec Králové, Rokitanskeho 62,, 500 03, Hradec Kralove, Czech Republic.
700    1_
$a Brodak, Milos $u Medical School and Teaching Hospital, Department of Urology, Charles University, Sokolska 581,, 500 05, Hradec Kralove, Czech Republic.
700    1_
$a Pfohl-Leszkowicz, Annie $u INP/ENSAT Toulouse, Department Bioprocess & Microbial Systems, Laboratory Chemical Engineering, University of Toulouse, 31320, Auzeville-Tolosane, France.
700    1_
$a Degen, Gisela H $u Leibniz Research Centre for Working Environment and Human Factors (IfADo), Ardeystrasse 67, 44139, Dortmund, Germany.
773    0_
$w MED00192822 $t Mycotoxin research $x 1867-1632 $g Roč. 35, č. 4 (2019), s. 391-403
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31254204 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200526143703 $b ABA008
999    __
$a ok $b bmc $g 1525059 $s 1096257
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 35 $c 4 $d 391-403 $e 20190629 $i 1867-1632 $m Mycotoxin research $n Mycotoxin Res $x MED00192822
GRA    __
$a 2118/2015 $p University Hradec Kralove, Czech Republic
GRA    __
$a 2113/2016 $p University Hradec Kralove, Czech Republic
GRA    __
$a 2105/2017 $p University Hradec Kralove, Czech Republic
GRA    __
$a NIPH, IN 75010330 $p Ministry of Health, Czech Republic conceptual development of research organization
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace